8-K: Moleculin Biotech Announces 1-for-25 Reverse Stock Split

Moleculin Biotech, Inc. will implement a 1-for-25 reverse stock split effective December 1, 2025, to consolidate shares and maintain its Nasdaq listing.

Summary

• A 1-for-25 reverse stock split of common stock will become effective at 12:01 a.m. Eastern Time on December 1, 2025.
• The company's common stock will trade on The Nasdaq Capital Market on a post-split basis under the existing ticker symbol MBRX with a new CUSIP number 60855D408.
• Every 25 shares of issued and outstanding common stock will automatically combine into one share, without changing the par value of $0.001 per share.
• The number of outstanding common shares will reduce from approximately 51.6 million to approximately 2.07 million, while authorized shares remain at 500 million.
• Fractional shares will not be issued; stockholders will receive cash payments based on the average closing sales prices over the five trading days preceding the split.
• Proportionate adjustments will be made to outstanding stock options, restricted stock unit awards, and warrants, including exercise prices and number of issuable shares.
• Specific adjustments apply to Series E and F warrants, potentially reducing their exercise price to the lowest daily volume-weighted average price during a 10-day period around the split, with Series E warrants also having a $3.00 per share floor price.
• The company reported a net loss of $(26,048) thousand for the year ended December 31, 2024, resulting in a post-split net loss per common share of $(189.14).
• For the nine months ended September 30, 2025, the net loss was $(49,112) thousand, with a post-split net loss per common share of $(58.95).

Sentiment

Score: 4

Explanation: The reverse stock split is a necessary action to maintain Nasdaq listing, which is a positive for market access. However, it underscores persistent financial challenges, including significant net losses and an explicit need for substantial, uncommitted future financing to fund ongoing clinical trials. This creates considerable uncertainty and risk for investors.

Positives

• The reverse stock split is a necessary corporate action to maintain compliance with Nasdaq listing requirements, preventing potential delisting.
• The company continues to advance its pipeline of therapeutic candidates, including Annamycin in Phase 3 clinical trials for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
• The MIRACLE Trial (MB-108) for Annamycin in AML is a pivotal, adaptive design Phase 3 trial, indicating progress in its lead program.
• Management believes the development pathway for Annamycin in AML is substantially de-risked following a successful Phase 1B/2 study (MB-106) and FDA input.

Negatives

• The company continues to incur significant net losses, reporting $(26,048) thousand for the year ended December 31, 2024, and $(49,112) thousand for the nine months ended September 30, 2025.
• The reverse stock split, while necessary for listing, often signals underlying financial challenges or a sustained low share price, which can be viewed negatively by the market.
• The company explicitly states it will require "significant additional financing" for its clinical trials, for which it currently has "no commitments."
• The substantial increase in net loss per common share post-split (e.g., from $(7.57) to $(189.14) for 2024) highlights the dilution and operational losses.

Risks

• The company requires significant additional financing to conduct its clinical trials, and there are no current commitments for such funding.
• The milestones described for clinical trials assume the company's ability to secure financing on a timely basis, which is uncertain.
• Forward-looking statements involve known and unknown risks, uncertainties, and other factors, including those discussed in the company's Form 10-K and 10-Q filings.
• The success of clinical trials for Annamycin, WP1066, and WP1122 is not guaranteed and is subject to regulatory approvals and trial outcomes.
• The potential for further dilution exists if future capital raises involve issuing new equity.

Future Outlook

The company is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is in a pivotal Phase 3 trial (MIRACLE Trial MB-108) for relapsed or refractory acute myeloid leukemia (AML) and is also being developed for soft tissue sarcoma (STS) lung metastases. The company also has WP1066 targeting brain tumors, pancreatic, and other cancers, and WP1122 for pathogenic viruses and certain cancer indications. The ability to achieve future milestones is contingent upon securing significant additional financing, for which there are currently no commitments.

Management Comments

• Moleculin Biotech, Inc. today announced that it led an amendment to its amended and restated certicate of incorporation with the Secretary of State of the State of Delaware to eect a 1-for-25 reverse stock split of its common stock.
• Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML.

Industry Context

Reverse stock splits are a common strategy for clinical-stage biotechnology companies like Moleculin Biotech to maintain compliance with stock exchange listing requirements, particularly minimum bid price rules. This action allows the company to continue trading on Nasdaq, which is crucial for access to capital markets and investor visibility. However, it also highlights the inherent challenges of drug development, including significant capital requirements and the long, uncertain path to commercialization, which often leads to sustained net losses and low stock prices. The need for "significant additional financing" is typical for companies in this stage, as drug development is highly capital-intensive.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience a reduction in the number of shares held (1-for-25 ratio) but a proportional increase in the per-share price. Fractional shares will be cashed out. The action aims to maintain Nasdaq listing, which benefits shareholders by ensuring continued market access. However, the underlying financial performance (net losses) and the need for future financing pose ongoing risks of dilution or value erosion.
• Investment Professionals/Analysts: Will need to adjust financial models and analyses to reflect the post-split share count and per-share metrics. The reverse split may trigger re-evaluation of the company's financial health and long-term viability, especially concerning its ability to secure future funding.

Next Steps

• The 1-for-25 reverse stock split will become effective on December 1, 2025.
• The company will continue to advance its lead program, Annamycin, in the pivotal Phase 3 MIRACLE Trial (MB-108) for relapsed or refractory acute myeloid leukemia.
• Further development of WP1066 for brain tumors, pancreatic, and other cancers.
• Further development of WP1122 for pathogenic viruses and certain cancer indications.
• Securing significant additional financing to fund ongoing clinical trials.

Key Dates

Recommendation

The reverse stock split is a technical maneuver to maintain Nasdaq listing, which is a positive for market access and liquidity. However, it does not address the fundamental challenges of significant ongoing net losses and the explicit need for substantial, uncommitted financing to fund critical clinical trials. While the company has promising drug candidates in development, the high capital requirements and inherent risks of clinical-stage biotech make it a speculative investment. Existing investors should hold to monitor clinical trial progress and financing developments, while new investors might find the risk-reward profile less attractive given the immediate need for capital.

Keywords

Biotech, Reverse Stock Split, MBRX, Nasdaq, Clinical Stage, Pharmaceutical, Annamycin, Acute Myeloid Leukemia, Soft Tissue Sarcoma, Oncology, Drug Development, Corporate Action, Financing Risk